WAM
ALNY icon

Wealthspire Advisors (Maryland)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-538
Closed -$50K – 516
2019
Q1 		$50K Buy
538
+447
+491% +$37.4K ﹤0.01% 890
2018
Q4 		$7K Buy
91
+2
+2% +$154 ﹤0.01% 1585
2018
Q3 		$8K Buy
89
+18
+25% +$1.81K ﹤0.01% 1589
2018
Q2 		$7K Sell
71
-19
-21% -$1.89K ﹤0.01% 1647
2018
Q1 		$11K Buy
90
+22
+32% +$2.84K ﹤0.01% 1513
2017
Q4 		$9K Buy
68
+46
+209% +$5.78K ﹤0.01% 1615
2017
Q3 		$3K Buy
22
+3
+16% +$256 ﹤0.01% 1891
2017
Q2 		$2K Buy
19
+7
+58% +$447 ﹤0.01% 1960
2017
Q1 		$1K Buy
+12
New +$555 ﹤0.01% 1762
2016
Q2 		– Sell
-6
Closed – – 1683
2016
Q1 		$0 Sell
6
-3
-33% -$199 ﹤0.01% 1736
2015
Q4 		$1K Buy
+9
New +$834 ﹤0.01% 1588

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ALNY Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 538 shares — an estimated $50K sold.

Wealthspire Advisors (Maryland) first reported a position in ALNY in Q4 2015 and held it in 11 quarters. The position peaked at $50K in Q1 2019. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 538 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $50K.
  • Wealthspire Advisors (Maryland) first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 11 quarters.
  • Wealthspire Advisors (Maryland)'s Alnylam Pharmaceuticals position peaked at $50K in Q1 2019.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.